Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

There is an urgent need to develop treatments for patients with melanoma who are refractory to or ineligible for immune checkpoint blockade, including patients who lack BRAF-V600E/K mutations. This is often the case in patients diagnosed with rare melanoma subtypes such as mucosal and acral melanoma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Mukherjee, Nabanita, Amato, Carol M., Skees, Jenette, Todd, Kaleb J., Lambert, Karoline A., Robinson, William A., Van Gulick, Robert, Weight, Ryan M., Dart, Chiara R., Tobin, Richard P., McCarter, Martin D., Fujita, Mayumi, Norris, David A., Shellman, Yiqun G.
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7464298/
https://ncbi.nlm.nih.gov/pubmed/32764384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082182
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados